Name | 4-[3-(trifluoromethyl)pyridin-2-yl]-N-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide |
---|---|
Synonyms |
unii-71je0c439x
JNJ-17203212 |
Description | JNJ-17203212 is a novel and selective TRPV1 antagonist, with IC50 of 65 nM and 102 nM for human TRPV1 and rat TRPV1.IC50 value: 65 nM (human TRPV1), 102 nM (rat TRPV1)Target: TRPVin vivo: JNJ-17203212 reduces sensitivity to luminal distension in both an acute, noninflammatory and a chronic, post-inflammatory rodent model of colonic hypersensitivity. Throughout this study, colonic sensitivity was assessed via quantification of VMR to CRD in rats following a single, oral administration of JNJ-17203212 (3, 10 or 30 mg/kg) or vehicle. [1] Oral pretreatment with JNJ-17203212 is a novel and selective TRPV1 antagonist, with partially prevents core hypothermia evoked by sc capsaicin. Oral pretreatment with JNJ-17203212 is a novel and selective TRPV1 antagonist, with partially prevents capsaicin-evoked hypothermia in a dose-response manner. [2] |
---|---|
Related Catalog | |
References |
Molecular Formula | C17H15F6N5O |
---|---|
Molecular Weight | 419.32400 |
Exact Mass | 419.11800 |
PSA | 61.36000 |
LogP | 3.94420 |
Storage condition | 2-8℃ |
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301-H319 |
Precautionary Statements | P301 + P310-P305 + P351 + P338 |
RIDADR | UN 2811 6.1 / PGIII |